Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25084297 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rubén Osuna-Gómez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain. Hauptthemen laut MEDLINE: Muramidase, Secretory Leukocyte Peptidase Inhibitor, Bronchoalveolar Lavage Fluid, Lung Diseases, Interstitial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interstitial lung diseases (ILDs) are characterized by inflammation or fibrosis of the pulmonary parenchyma. Despite the involvement of immune cells and soluble mediators in pulmonary fibrosis, the influence of antimicrobial peptides (AMPs) remains underexplored. These effector molecules display a range of activities, which include immunomodulation and wound repair. Here, we investigate the role of AMPs in the development of fibrosis in ILD. We compare the concentration of different AMPs and different cytokines in 46 fibrotic (F-ILD) and 17 non-fibrotic (NF-ILD) patients by ELISA and using peripheral blood mononuclear cells from in vitro stimulation in the presence of lysozyme or secretory leukocyte protease inhibitor (SLPI) from 10 healthy donors. We observed that bronchoalveolar lavage (BAL) levels of AMPs were decreased in F-ILD patients (lysozyme: p < 0.001; SLPI: p < 0.001; LL-37: p < 0.001; lactoferrin: p = 0.47) and were negatively correlated with levels of TGF-β (lysozyme: p = 0.02; SLPI: p < 0.001) and IL-17 (lysozyme: p < 0.001; SLPI: p < 0.001). We observed that lysozyme increased the percentage of CD86+ macrophages (p < 0.001) and the production of TNF-α (p < 0.001). We showed that lysozyme and SLPI were associated with clinical parameters (lysozyme: p < 0.001; SLPI: p < 0.001) and disease progression (lysozyme: p < 0.001; SLPI: p = 0.01). These results suggest that AMPs may play an important role in the anti-fibrotic response, regulating the effect of pro-fibrotic cytokines. In addition, levels of lysozyme in BAL may be a potential biomarker to predict the progression in F-ILD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammatory Diseases, Institut de Recerca Sant Pau (IR Sant Pau), 08041 Barcelona, Spain.
- Respiratory Department, Institut de Recerca Biomèdica de Lleida (IRBLleida), Hospital Universitari Arnau de Vilanova-Santa María, Translational Research in Respiratory Medicine, Universitat de Lleida (UdL), 25198 Lleida…
- Department of Respiratory, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
- Department of Respiratory, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain.
ORCID-Profile: Rubén Osuna-Gómez, Maria Mulet, David de la Rosa-Carrillo, Diego Castillo, Silvia Vidal
Zitieren
APA
Osuna-Gómez, R., Mulet, M., Barril, S., Cantó, E., Millan-Billi, P., Pardessus, A., de la Rosa-Carrillo, D., Castillo, D., & Vidal, S. (2024). Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084297
Vancouver
Osuna-Gómez R, Mulet M, Barril S, Cantó E, Millan-Billi P, Pardessus A, et al. Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084297
BibTeX
@article{OsunaGmez2024,
author = {Osuna-Gómez, Rubén and Mulet, Maria and Barril, Silvia and Cantó, Elisabet and Millan-Billi, Paloma and Pardessus, Ana and de la Rosa-Carrillo, David and Castillo, Diego and Vidal, Silvia},
title = {Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25084297}
}
EUVIMED